DAPAGLIFLOZIN
SYNTHESIS http://newdrugapprovals.org/2013/12/18/dapagliflozin-sees-light/
AstraZeneca announced that the Scottish Medicines Consortium (SMC) has issued positive advice for use of its Forxiga, a selective and reversible inhibitor of sodium-glucose co-transporter-2, as part of a triple therapy regimen for type 2 diabetes.
Filed under: Scottish Medicines Consortium Tagged: ASTRAZENECA, DAPAGLIFLOZIN, FORXIGA, positive advice, reversible inhibitor, Scottish Medicines Consortium, triple therapy regimen
